Best Practice & Research Clinical Gastroenterology
Volume 25, Issue 6 , Pages 653-664 , December 2011

Pathogenesis of autoimmune hepatitis

  • Rodrigo Liberal, MD

      Affiliations

    • Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, Denmark Hill, London SE5 9RS, UK
    • Faculty of Medicine, University of Porto, Porto, Portugal
    • ,
  • Maria Serena Longhi, MD, PhD

      Affiliations

    • Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, Denmark Hill, London SE5 9RS, UK
    • ,
  • Giorgina Mieli-Vergani, MD, PhD, FRCP

      Affiliations

    • Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, Denmark Hill, London SE5 9RS, UK
    • ,
  • Diego Vergani, MD, PhD, FRCP

      Affiliations

    • Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, Denmark Hill, London SE5 9RS, UK
    • Corresponding Author InformationCorresponding author. Tel: +44 207 3463305; fax: +44 207 3463700.

References 

  1. Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut. 2004;53:599–608
  2. Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis. 2002;22:353–364
  3. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6:727–737
  4. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 1991;13:701–706
  5. Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997;112:2028–2035
  6. Donaldson PT. Genetics of autoimmune and viral liver diseases; understanding the issues. J Hepatol. 2004;41:327–332
  7. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev. 2000;174:250–259
  8. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci. 2002;47:2139–2150
  9. Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol. 2009;31:421–435
  10. Duarte-Rey C, Pardo AL, Rodriguez-Velosa Y, Mantilla RD, Anaya JM, Rojas-Villarraga A. HLA class II association with autoimmune hepatitis in Latin America: a meta-analysis. Autoimmun Rev. 2009;8:325–331
  11. Ma Y, Bogdanos DP, Hussain MJ, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology. 2006;130:868–882
  12. Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol. 2004;40:904–909
  13. Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol. 2006;45:844–850
  14. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 1997;25:541–547
  15. Vorechovsky I, Webster AD, Plebani A, Hammarstrom L. Genetic linkage of IgA deficiency to the major histocompatibility complex: evidence for allele segregation distortion, parent-of-origin penetrance differences, and the role of anti-IgA antibodies in disease predisposition. Am J Hum Genet. 1999;64:1096–1109
  16. Vergani D, Wells L, Larcher VF, et al. Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis. Lancet. 1985;2:294–298
  17. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology. 2000;31:49–53
  18. Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol. 2008;14:3306–3312
  19. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999;117:645–652
  20. Yoshizawa K, Ota M, Katsuyama Y, et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol. 2005;42:578–584
  21. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007;69:227–235
  22. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology. 2002;35:126–131
  23. Mathis D, Benoist C. Aire Annu Rev Immunol. 2009;27:287–312
  24. Simmonds MJ, Gough SC. Genetic insights into disease mechanisms of autoimmunity. Br Med Bull. 2004;71:93–113
  25. Liston A, Gray DH, Lesage S, et al. Gene dosage–limiting role of Aire in thymic expression, clonal deletion, and organ-specific autoimmunity. J Exp Med. 2004;200:1015–1026
  26. Liston A, Lesage S, Gray DH, Boyd RL, Goodnow CC. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. Immunol Rev. 2005;204:87–101
  27. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2010;34:7–14
  28. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006;43:S54–S62
  29. Mackay IR. Hepatoimmunology: a perspective. Immunol Cell Biol. 2002;80:36–44
  30. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147–163
  31. Nouri-Aria KT, Hegarty JE, Alexander GJ, Eddleston AL, Williams R. Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. N Engl J Med. 1982;307:1301–1304
  32. Hodgson HJ, Wands JR, Isselbacher KJ. Alteration in suppressor cell activity in chronic active hepatitis. Proc Natl Acad Sci U S A. 1978;75:1549–1553
  33. Vento S, Hegarty JE, Bottazzo G, Macchia E, Williams R, Eddleston AL. Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet. 1984;1:1200–1204
  34. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+)regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31–37
  35. Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4 + CD25 + regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63–71
  36. Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4 + CD25+regulatory T-cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484–4491
  37. Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T-cells in patients with autoimmune hepatitis. Hepatology. 2008;47:581–591
  38. Ferri S, Longhi MS, De Molo C, et al. A multifaceted imbalance of T-cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology. 2010;52:999–1007
  39. Longhi MS, Hussain MJ, Kwok WW, Mieli-Vergani G, Ma Y, Vergani D. Autoantigen-specific regulatory T-cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology. 2011;53:536–547
  40. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3 + regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500
  41. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–532
  42. Janson PC, Winerdal ME, Marits P, Thorn M, Ohlsson R, Winqvist O. FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One. 2008;3:e1612
  43. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3 + T regulatory cells. J Immunol. 2010;184:3433–3441
  44. Longhi MS, Mitry RR, Samyn M, et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology. 2009;50:130–142
  45. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009;30:656–665
  46. Akbar AN, Taams LS, Salmon M, Vukmanovic-Stejic M. The peripheral generation of CD4 + CD25 + regulatory T cells. Immunology. 2003;109:319–325
  47. Longhi MS, Liberal R, Mieli-Vergani G, Ma Y, Vergani D. Inhibition of Th17-cells enhances the suppressor function of de novo generated T-Reg in patients with autoimmune hepatitis. Hepatology. 2011;50:1012a-a
  48. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238
  49. Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver-kidney-microsome-antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med. 1988;168:801–806
  50. Kerkar N, Choudhuri K, Ma Y, et al. Cytochrome P4502D6(193–212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol. 2003;170:1481–1489
  51. Longhi MS, Hussain MJ, Bogdanos DP, et al. Cytochrome P450IID6-specific CD8 T-cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology. 2007;46:472–484
  52. Santodomingo-Garzon T, Swain MG. Role of NKT cells in autoimmune liver disease. Autoimmun Rev. 2011;
  53. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225–232
  54. Gregorio GV, Choudhuri K, Ma Y, Vegnente A, Mieli-Vergani G, Vergani D. Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. J Immunol. 1999;162:1802–1810
  55. Gregorio GV, Choudhuri K, Ma Y, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol. 2003;133:404–413
  56. Lenzi M, Bellentani S, Saccoccio G, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut. 1999;45:435–441
  57. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 1991;88:1370–1378
  58. Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child. 1992;67:1447–1453
  59. Lobo-Yeo A, Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology. 1990;12:224–232
  60. Senaldi G, Lobo-Yeo A, Mowat AP, Mieli-Vergani G, Vergani D. Class I and class II major histocompatibility complex antigens on hepatocytes: importance of the method of detection and expression in histologically normal and diseased livers. J Clin Pathol. 1991;44:107–114
  61. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888–898
  62. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485–517
  63. Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol. 2009;157:261–270
  64. Zhao L, Tang Y, You Z, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011;6:e18909
  65. Jensen DM, McFarlane IG, Portmann BS, Eddleston AL, Williams R. Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med. 1978;299:1–7
  66. McFarlane BM, McSorley CG, Vergani D, McFarlane IG, Williams R. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol. 1986;3:196–205
  67. Vergani GM, Vergani D, Jenkins PJ, et al. Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin Exp Immunol. 1979;38:16–21
  68. Vergani D, Mieli-Vergani G, Mondelli M, Portmann B, Eddleston AL. Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver. 1987;7:307–315
  69. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658–664
  70. Muratori L, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut. 2000;46:553–561
  71. Ma Y, Thomas MG, Okamoto M, et al. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J Immunol. 2002;169:277–285
  72. Wen L, Peakman M, Lobo-Yeo A, et al. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet. 1990;336:1527–1530
  73. Wen L, Ma Y, Bogdanos DP, et al. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med. 2001;1:379–389
  74. Lohr H, Manns M, Kyriatsoulis A, et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol. 1991;84:297–302
  75. Kreslavsky T, Gleimer M, Garbe AI, von Boehmer H. alphabeta versus gammadelta fate choice: counting the T-cell lineages at the branch point. Immunol Rev. 2010;238:169–181
  76. Wen L, Peakman M, Mieli-Vergani G, Vergani D. Elevation of activated gamma delta T cell receptor bearing T lymphocytes in patients with autoimmune chronic liver disease. Clin Exp Immunol. 1992;89:78–82
  77. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology. 2004;39:1066–1074
  78. Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409–1422

PII: S1521-6918(11)00086-2

doi: 10.1016/j.bpg.2011.09.009

Best Practice & Research Clinical Gastroenterology
Volume 25, Issue 6 , Pages 653-664 , December 2011

Article Tools

* Image Usage & Resolution